Breast cancer subtype and clinical characteristics in women from Peru.

Autor:	Zavala VA; Department of Public Health Sciences, University of California, Davis, Davis, CA, United States., Casavilca-Zambrano S; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Patología, Lima, Peru., Navarro-Vásquez J; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Investigación, Lima, Peru., Tamayo LI; Department of Public Health Sciences, The University of Chicago, Chicago, IL, United States., Castañeda CA; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Valencia G; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Morante Z; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Calderón M; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Abugattas JE; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía de Mamas y tumores Blandos, Lima, Peru., Gómez HL; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Fuentes HA; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Liendo-Picoaga R; Instituto Nacional de Enfermedades Neoplásicas, Banco de Tumores, Lima, Peru., Cotrina JM; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía de Mamas y tumores Blandos, Lima, Peru., Neciosup SP; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Roque K; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Vásquez J; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Mas L; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Gálvez-Nino M; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru., Fejerman L; Department of Public Health Sciences, University of California, Davis, Davis, CA, United States.; University of California Davis Comprehensive Cancer Center, University of California, Davis, Davis, CA, United States., Vidaurre T; Instituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Feb 16; Vol. 13, pp. 938042. Date of Electronic Publication: 2023 Feb 16 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.938042
Abstrakt:	Introduction: Breast cancer is a heterogeneous disease, and the distribution of the different subtypes varies by race/ethnic category in the United States and by country. Established breast cancer-associated factors impact subtype-specific risk; however, these included limited or no representation of Latin American diversity. To address this gap in knowledge, we report a description of demographic, reproductive, and lifestyle breast cancer-associated factors by age at diagnosis and disease subtype for The Peruvian Genetics and Genomics of Breast Cancer (PEGEN-BC) study. Methods: The PEGEN-BC study is a hospital-based breast cancer cohort that includes 1943 patients diagnosed at the Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru. Demographic and reproductive information, as well as lifestyle exposures, were collected with a questionnaire. Clinical data, including tumor Hormone Receptor (HR) status and Human Epidermal Growth Factor Receptor 2 (HER2) status, were abstracted from electronic medical records. Differences in proportions and mean values were tested using Chi-squared and one-way ANOVA tests, respectively. Multinomial logistic regression models were used for multivariate association analyses. Results: The distribution of subtypes was 52% HR+HER2-, 19% HR+HER2+, 16% HR-HER2-, and 13% HR-HER2+. Indigenous American (IA) genetic ancestry was higher, and height was lower among individuals with the HR-HER2+ subtype (80% IA vs. 76% overall, p =0.007; 152 cm vs. 153 cm overall, p =0.032, respectively). In multivariate models, IA ancestry was associated with HR-HER2+ subtype (OR=1.38,95%CI=1.06-1.79, p =0.017) and parous women showed increased risk for HR-HER2+ (OR=2.7,95%CI=1.5-4.8, p <0.001) and HR-HER2- tumors (OR=2.4,95%CI=1.5-4.0, p <0.001) compared to nulliparous women. Multiple patient and tumor characteristics differed by age at diagnosis (<50 vs. >=50), including ancestry, region of residence, family history, height, BMI, breastfeeding, parity, and stage at diagnosis ( p <0.02 for all variables). Discussion: The characteristics of the PEGEN-BC study participants do not suggest heterogeneity by tumor subtype except for IA genetic ancestry proportion, which has been previously reported. Differences by age at diagnosis were apparent and concordant with what is known about pre- and post-menopausal-specific disease risk factors. Additional studies in Peru should be developed to further understand the main contributors to the specific age of onset and molecular disease subtypes in this population and develop population-appropriate predictive models for prevention. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Zavala, Casavilca-Zambrano, Navarro-Vásquez, Tamayo, Castañeda, Valencia, Morante, Calderón, Abugattas, Gómez, Fuentes, Liendo-Picoaga, Cotrina, Neciosup, Roque, Vásquez, Mas, Gálvez-Nino, Fejerman and Vidaurre.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu